This study will involve 12 babies who have been identified as at risk for withdrawal symptoms after birth. This study will test the feasibility of acupressure as an additional non-invasive, first line treatment for infants experiencing withdrawal symptoms. We will also send a voluntary survey out to the healthcare providers who cared for the infant (nurse, medical doctor, or advanced practice provider (nurse practitioner or physician assistant).
This study aims to show the safety and effectiveness of AMAG-423, an IV medication, in women with severe preeclampsia. The purpose of this study is to see how well AMAG-423 might work to prevent some of the most serious complications in premature babies, as well as improve symptoms of preeclampsia. Women will be admitted with this diagnosis and receive IV medication, AMAG-423, every 6 hours for up to 4 days. Subjects will be followed through out their hospital stay and up until their post partum 6 week check. The only treatment for severe preeclampsia is delivery.
The purpose of this research study is to test the safety and effectiveness of an investigational drug (Solosec) for the treatment of trichomoniasis. Solosec was approved in the United States by the Food and Drug Administration (FDA) in 2017 for the treatment of bacterial vaginosis (BV) in adult women ages 18 years and older. The sponsor would like to gather additional information for the treatment of Solosec in adult women and girls ages 12 years and older diagnosed with trichomoniasis.
Staff at sites who participate in the MUSC Women's Reproductive Behavioral Telehealth (WRBT) Program will be asked to participate in individual interviews or focus groups (group discussions) about their experience with the telemedicine program and fill out surveys. Patients in the WRBT Program will be asked to fill out surveys about their telemedicine experience.
The purpose of this research is to provide the sponsor vaginal and urine samples that the clinician has collected and the subject has self collected in order to study a new test being developed for the detection of Chlamydia trachomatis and
This purpose of this research study is to collect feedback from participants about a web-based program for opioid misuse and opioid use disorder. Participants will be asked to review web-based content and take part in focus groups (group discussions) and individual interviews to provide feedback on the content. The study team is looking for pregnant women or women who have been pregnant in the past 2 years who misuse opioids or have opioid use disorder, as well as obstetric providers who treat pregnant women with opioid misuse and opioid use disorder to participate.
Preeclamptic patients will have an ultrasound done of their eyes, to look at the size of the nerve behind the eye. We will also recruit women without preeclampsia to be a comparison group.
We propose to play the song "Weightless" during epidural placement on an iPhone set to medium volume. The song (all 6 continual parts) is 43 minutes long and will be started just before epidural placement and stopped just after end of procedure. The control group will be expectant mothers who do not have "Weightless" playing during their epidural placement. The goal is to determine if playing "the most relaxing song in the world" helps to reduce laboring parturients anxiety and improve their overall satisfaction with the experience.
The primary investigators/residents have noted during clinical rotations that a significant number of GBS unknown mothers at SRHS are being treated with intrapartum antibiotics even without the presence of risk factors, presumably to decrease postpartum/neonatal length of stay.
Our study, a retrospective chart review, will determine whether or not length of stay is affected by treating GBS unknown mothers with intrapartum antibiotics in the absence of the aforementioned risk factors.
Potential benefits include the cost-effectiveness of decreased length of stay for these patients as well as decreased exposure to nosocomial infections for neonates. However, antibiotic stewardship and patient safety are also considerations. Another potential option for these patients is rapid GBS testing with PCR which can provide results in 1-2 hours compared with 24-48 hours for the standard culture. PCR is not currently available at SMC.
Bayer is studying an investigational drug, Vilaprasin, in women who have been diagnosed with uterine fibroids vs standard treatment.